Early detection and management of inborn errors of metabolism (IEMs) can improve the affected infant's prognosis. Initial screening tests can provide a general overview of the infant's metabolic status and suggest potential IEMs. Among the clinical findings seen in many IEMs are encephalopathy, hypoglycemia, jaundice and liver disease, cardiac arrhythmias, cardiomyopathy, hypotonia, dysmorphic features, and nonimmune hydrops. Confirmatory testing (enzyme analysis or molecular DNA testing) are required to make the diagnosis. Clinicians should be aware of specific requirements for such testing to obtain the desired results.
Introduction
Many IEMs present in the newborn period, and early detection and management can improve an infant's prognosis substantially. The advent of extended newborn screening has made presymptomatic diagnosis of a number of these disorders possible. However, not all IEMs are identified on an extended newborn screen, and in some instances, an infant who has an IEM may become ill before the results of newborn screening become available. It is, therefore, important for the neonatologist to consider an inborn error of metabolism in the differential diagnosis for an acutely sick neonate and initiate appropriate testing.
Sudden deterioration after a period of apparent normalcy is highly suggestive of a metabolic disorder. A neonate who has an IEM may present with symptoms that frequently are attributed to more common neonatal conditions, such as sepsis or gastrointestinal pathology, which may lead to a delayed or missed diagnosis. Signs such as an unusual odor (as in maple syrup urine disease), posturing (as in glutaric acidemia type 1), or apnea (as in nonketotic hyperglycinemia) can indicate an IEM. Parental consanguinity or a family history of neonatal death also should alert the physician to the possibility of a genetic disorder.
In this review, we discuss the laboratory testing strategy that may be considered in the initial evaluation of a possible IEM. Discussion of the treatment of metabolic disorders is beyond the scope of this review. metabolic status of the neonate and suggest IEMs that might be considered in the differential diagnosis (Table 2) .
Some IEMs have characteristic presentations, but initial test results are normal. These presentations and appropriate testing are discussed in the relevant sections of this article.
Encephalopathy
An infant who has encephalopathy can present with seizures, lethargy, or poor feeding that may be associated with metabolic abnormalities such as hyperammonemia and metabolic acidosis. Occasionally, an infant who has encephalopathy and an IEM may present with no other supporting laboratory abnormalities.
Encephalopathy associated with hyperammonemia can be a feature of several inborn errors, which can be differentiated based on initial test results (Fig. 1) . Elevated ammonia concentration within 24 hours of birth with normal plasma amino acids values suggests the diagnosis of transient hyperammonemia of newborn, a Encephalopathy associated with metabolic acidosis due to inborn errors of metabolism usually is characterized by an increased anion gap. It is important to determine the source of this increase. Lactic acidosis is encountered commonly and if mild, usually is due to cardiovascular compromise. Unexplained elevation of lactic acid requires the consideration of a metabolic disorder (Fig. 2) . In addition, an acylcarnitine profile can aid in the diagnosis of fatty acid oxidation disorders and organic acidemias.
Some IEMs can present with an encephalopathic picture without hyperammonemia or metabolic acidosis. Maple syrup urine disease (MSUD) is caused by an inability to break down branched-chain amino acids such as leucine, isoleucine, and valine, and a plasma amino acid profile is diagnostic. Ketoacidosis is observed in MSUD but may be absent at initial presentation. Nonketotic hyperglycinemia is caused by an inability to breakdown glycine in the liver and is characterized by a severe encephalopathy with no other associated abnormalities. Plasma amino acids may show an elevated glycine, and supporting laboratory results may be noncontributory. In this clinical scenario, it is essential to obtain cerebrospinal fluid to measure glycine concentrations, which can be diagnostic.
Pyridoxine-dependent seizures present as severe, intractable seizures within the first few hours of birth. This disorder is marked by a dramatic response to vitamin B6 administration. Severe seizures and encephalopathy usually developing in the first postnatal week also can suggest molybdenum cofactor deficiency. This is associated with combined deficiencies of the two enzymes that depend on molybdenum: xanthine oxidase and sulfite oxidase. In xanthine oxidase deficiency, uric acid is markedly decreased (not seen in isolated sulfite oxidase deficiency). The presence of sulfite in a fresh urine sample using a special dipstick test may be suggestive of this condition. However, elevated S-sulfocysteine concentrations in urine are more definitive.
Hypoglycemia
Hypoglycemia is a relatively common neonatal concern. Unexplained hypoglycemia may be caused by IEMs due to defects in carbohydrate metabolism and fatty acid oxidation. Occasionally, protein metabolism defects can have associated hypoglycemia, but other metabolic disturbances predominate.
The tests listed in Table 1 should be ordered, with the addition of urine for reducing substances (Fig. 3) . If nonglucose reducing substances are present in the urine, galactosemia, hereditary fructose intolerance, or tyrosinemia should be considered. Abnormally low ketones in the presence of hypoglycemia may be indicative of a fatty acid oxidation disorder. Fatty acid oxidation disorders are important because of their relatively high prevalence and usually are identified based on acylcarnitine profile abnormalities. Affected infants have an impaired capacity to use stored fats in periods of extended fasting. The presentation may be similar to Reye syndrome, with metabolic acidosis, hyperammonemia, and elevated liver enzymes, particularly transaminases.
Hepatic glycogen storage diseases (GSDs), especially type I, cause hypoglycemia during periods of fasting. The diagnosis of GSD type I may be missed in the neonatal period because the hypoglycemia resolves when regular feeding is established. The liver is mildly enlarged in the first 2 postnatal days but can be markedly enlarged by the end of the first week. Abnormal laboratory study results that indicate the diagnosis of GSD type I include lactic acidosis, hyperuricemia, and hypoglycemia. 
Jaundice and Liver Disease
Unconjugated hyperbilirubinemia may be seen in inborn errors of erythrocyte and bilirubin metabolism. Glucose-6-phosphate dehydrogenase (G6PD) deficiency and pyruvate kinase deficiency can present in the newborn period with unconjugated hyperbilirubinemia due to hemolysis. Nonspherocytic hemolytic anemia, as noted on peripheral smear, helps in diagnosis, which can be confirmed by enzymatic analysis. Disorders of bilirubin metabolism, such as Gilbert, Crigler Najjar, DubinJohnson, and Lucey Driscoll syndromes, present with unconjugated hyperbilirubinemia and normal values for other liver function tests. Most of these disorders are benign. However, hyperbilirubinemia in type I Crigler Najjar syndrome may be severe enough to cause kernicterus. Most newborn screening programs include evaluation for classic galactosemia. It presents in the neonatal period with hyperbilirubinemia that is unconjugated in the early stages and predominantly conjugated in the later stages. If the neonate continues to be fed lactose-containing formula or human milk, the jaundice worsens, hepatomegaly appears, transaminases become elevated, and coagulopathy and hypoalbuminemia can occur. When classic galactosemia is suspected, urine and blood samples should be reserved for confirmatory testing, and the patient should be switched to a nongalactose-containing soy formula. The collected urine should be tested simultaneously with Benedict solution and a glucose oxidase method (urine dipsticks). A negative glucose oxidase test result and positive Benedict reagent reaction suggests the presence of a nonglucose reducing substance, and confirmatory testing can be undertaken.
Aminoacidopathies such as tyrosinemia type 1 and citrullinemia type 2 may present with severe liver disease and an abnormal plasma amino acid profile. Excretion of succinylacetone in the urine is diagnostic for tyrosinemia type 1. Fatty acid oxidation disorders also may present with hepatocellular dysfunction and are diagnosed based on an abnormal acylcarnitine profile.
Traditionally, hereditary fructose intolerance does not present in the neonatal period. However, affected infants who are exposed to fructose-containing feedings (as in sucrose-containing soy formulas) may develop acute hepatocellular failure, lactic acidosis, hyperuricemia, hyperchloremia, hypophosphatemia, and metabolic acidosis.
Alpha-1-antitrypsin deficiency presents with jaundice and cholestasis that may resolve spontaneously by 2 months of age only to present later with cirrhosis. The disorder is identified by low plasma concentrations of alpha-1-antitrypsin and is confirmed by protein phenotyping and mutation analysis. The perinatal form of GSD type IV presents with fetal hydrops and severe hypotonia. It often is rapidly fatal and is diagnosed by a liver biopsy. Niemann-Pick disease type C is a progressive neurodegenerative disease that can involve self-resolving jaundice and hepatomegaly in the neonatal period. Diagnosis often requires specialized studies on fibroblast cultures. Neonatal hemochromatosis can cause rapidly progressive liver failure and requires a liver biopsy for diagnosis. 
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Cardiac Presentation
In the newborn period, cardiac presentations of IEM include cardiac arrhythmias and cardiomyopathy. 
Dysmorphic Features
Subtle or overt dysmorphic features are observed in several metabolic disorders. Some disorders have a constellation of findings that can be diagnostic. Smith-Lemli-Opitz syndrome is a disorder of cholesterol synthesis associated with dysmorphic features, cleft palate, congenital heart disease, hypospadias, polydactyly, and syndactyly of the second and third toe. Serum cholesterol concentrations may be abnormally low or normal. An elevated plasma 7-dehydrocholesterol value is diagnostic. Zellweger syndrome is a peroxisomal disorder. Newborns have flat, expressionless faces with epicanthal folds and can be suspected initially to have Down syndrome. Hypotonia, cataracts, camptodactyly, and stippled epiphyses and patellae are observed. Zellweger syndrome, neonatal adrenoleukodystrophy, and other peroxisomal disorders are diagnosed by abnormal plasma very longchain fatty acid values.
Congenital disorders of glycosylation are rare conditions caused by abnormalities in glycoprotein synthesis. Several different types are described and have varying clinical features involving multiple organ systems. Type 1a is characterized by a broad nasal bridge, prominent jaw and forehead, and large ears as well as abnormal fat distribution, especially of the buttocks and thighs. The diagnosis is based on an isoelectric focusing pattern of transferrin isoforms.
Menkes disease is an X-linked disorder that should be suspected in a neonate who has hypothermia, hypotonia, jaundice, and characteristic facial features. Infants have macrocephaly with high foreheads and large anterior fontanelles. The hair is sparse and has a steely, kinky appearance. Skeletal radiographs show wormian bones, osteopenia, and metaphyseal widening. Copper and ceruloplasmin concentrations are decreased. Certain organic acidemias may be associated with multiple dysmorphic features. Neonates who have glutaric acidemia type II can have dysmorphic features, cerebral malformations, and cystic renal disease. Newborns affected by pyruvate dehydrogenase deficiency may have the facial features of fetal alcohol syndrome, agenesis of the corpus callosum, and cerebral atrophy. Because abnormal eye findings are seen in IEMs, an eye examination by an ophthalmologist is recommended.
Nonimmune Hydrops
Several disorders, including a number of IEMs, have been associated with nonimmune hydrops (Table 3) . It is important to note that in spite of a thorough evaluation, the cause of hydrops often is not identified.
Confirmatory Testing
Although metabolic screening tests are highly sensitive and specific for a particular diagnosis, confirmatory testing may be necessary. This often includes enzyme analysis or molecular DNA testing. Enzyme testing can be performed in various tissues such as leukocytes, skin fibroblasts, muscle, or liver. Prior to obtaining and sending out samples, it is important to review special criteria for collection and transport. Molecular testing to identify mutations in the gene coding for the enzyme may be available for certain disorders. Molecular testing is not always essential for making the diagnosis, but this information may help identify specific disease-causing mutations and aid in clinical correlation. Molecular testing is also useful in genetic counseling for at-risk family members and prenatal diagnosis.
Potential Testing Pitfalls
1. Although acutely ill neonates in metabolic crisis need immediate management, it is imperative to remember that the event provides a window of opportunity for optimal metabolic testing. At least 5 mL plasma and 5 mL urine should be set aside before correction of metabolic abnormalities. Blood spots dropped onto a filter paper (such as newborn screening cards), completely dried and stored with a desiccant, also may be saved for further analysis. 2. Expanded newborn screening provides valuable information but is still only a screen. When a metabolic disorder is suspected, the newborn screen results should not be the sole diagnostic evaluation; more definitive testing should be initiated. 3. When studies such as plasma amino acids, plasma acylcarnitine profile, and urine organic acids need to be sent to a specialized laboratory, they should be sent by overnight courier. Delay can affect results. 4. When ordering measurements of plasma amino acids, it is important to ask for a quantitative analysis. Analysis of amino acids generally is more informative in plasma rather than urine. Therefore, care must be taken to specify plasma amino acid analysis. 5. Free and total carnitine measurements often are ordered erroneously instead of the plasma acylcarnitine profile. The profile provides necessary information on different acylcarnitine moieties that can aid in diagnosis of fatty acid oxidation disorders. 6. Ammonia values can be significantly elevated if the sample is not immediately rushed on ice to the laboratory and analyzed. Accurate results rely on collecting a freeflowing blood sample and avoiding the use of a tight tourniquet. 7. Lactate and pyruvate concentrations must be obtained simultaneously for comparison. The same phlebotomy precautions should be taken as described for ammonia measurement. (Table 4) . This can present a stressful situation for the medical staff and family members, and a protocol should be established to help the process flow smoothly. When it is not feasible to retrieve such samples, a blood spot, dried on filter paper as described previously, should be obtained for possible metabolic or genetic testing. It is important to make every attempt to establish a diagnosis in a terminal newborn because such information is very important to the family for making future reproductive decisions.
Conclusion
Diagnosis of IEMs can be challenging. The testing strategy presented in this review aims to simplify the initial clinical approach to the diagnosis of these disorders.
A clinical geneticist should be involved when the initial test results are suggestive of a particular IEM to provide valuable assistance for confirmatory testing and management. 
